| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Found 29 studies with search of: | "Tipranavir"[TREATMENT] AND HIV [CONDITION] |
|
Hide studies that are not seeking new volunteers.
|
|
| 1 | Completed | Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Buprenorphine, Tipranavir and ritonavir | |||||
| 2 | Completed | Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Protease inhibitor tipranavir | |||||
| 3 | Active, not recruiting | Pharmacokinetic (PK) Study of Single-Dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Tipranavir; Drug: Ritonavir; Drug: Rosuvastatin | |||||
| 4 | Active, not recruiting | Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: tipranavir/ritonavir (dose reduction) | |||||
| 5 | Recruiting | Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Nevirapine; Drug: Efavirenz; Drug: Indinavir/ritonavir; Drug: Nelfinavir; Drug: Saquinavir/ritonavir; Drug: Lopinavir/ritonavir; Drug: Atazanavir; Drug: Atazanavir/ritonavir; Drug: Fos-amprenavir/ritonavir; Drug: Tipranavir/ ritonavir; Drug: Darunavir/ritonavir | |||||
| 6 | Available | Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Tipranavir Capsules; Drug: Tipranavir Oral Solution | |||||
| 7 | Completed | Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: tipranavir; Drug: ritonavir | |||||
| 8 | Active, not recruiting | Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2) | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Tipranavir (with low dose ritonavir) | |||||
| 9 | Completed | 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Tipranavir | |||||
| 10 | Recruiting | Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: lopinavir; Drug: atazanavir; Drug: efavirenz; Drug: fosamprenavir; Drug: darunavir; Drug: tipranavir; Drug: ritonavir; Drug: nevirapine; Drug: zidovudine; Drug: lamivudine; Drug: tenofovir; Drug: emtricitabine; Drug: abacavir | |||||
| 11 | Completed | Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST) | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Tipranavir/Ritonavir | |||||
| 12 | Completed | Safety Study of Tipranavir Co-Administered With Low-Dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Tipranavir/Ritonavir | |||||
| 13 | Completed | Tipranavir/Ritonavir (TPV/r) in Protease Inhibitor (PI)-Experienced Patients With HIV-1 Infection | ||||
| Condition: | HIV Infection | |||||
| Intervention: | Drug: Tipranavir co-administered with low dose ritonavir | |||||
| 14 | Terminated | SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: tipranavir; Drug: ritonavir | |||||
| 15 | Terminated | Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Tipranavir; Drug: Darunavir; Drug: Ritonavir | |||||
| 16 | Recruiting | Pharmaco-Epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safet & Efficacy | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: tipranavir | |||||
| 17 | Completed | Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together | ||||
| Condition: | HIV Infection | |||||
| Intervention: | Drug: apricitabine | |||||
| 18 | Active, not recruiting | HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) | ||||
| Conditions: | HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease | |||||
| Interventions: | Drug: Lamivudine; Drug: Stavudine; Drug: Didanosine; Drug: Zidovudine; Drug: Tenofovir; Drug: Abacavir; Drug: Efavirenz (EFV); Drug: Nevirapine; Drug: Indinavir; Drug: Saquinavir; Drug: Amprenavir; Drug: Ritonavir; Drug: Nelfinavir; Drug: Tipranavir; Drug: enfuvirtide (T20) | |||||
| 19 | Terminated | Safety and Antiviral Activuty of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: tipranavir; Drug: ritonavir | |||||
| 20 | Completed | Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: long term safety | |||||
| 21 | Recruiting | Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Nelfinavir; Drug: Lopinavir/ritonavir; Drug: Ritonavir; Drug: Amprenavir; Drug: Indinavir; Drug: Saquinavir; Drug: Fosamprenavir; Drug: Atazanavir; Drug: Tipranavir | |||||
| 22 | Completed | Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: tipranavir; Drug: ritonavir; Drug: saquinavir; Drug: amprenavir; Drug: lopinavir | |||||
| 23 | Recruiting | Optimizing Treatment for Treatment-Experienced, HIV Infected People | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Enfuvirtide; Drug: Raltegravir; Drug: Darunavir; Drug: Tipranavir; Drug: Etravirine; Drug: Maraviroc | |||||
| 24 | Recruiting | Observational Non-Interventional Study (Anwendungsbeobachtung) With Aptivus®(Tipranavir) in HIV-Infected Patients. | ||||
| Condition: | HIV Infections | |||||
| Intervention: | ||||||
| 25 | Recruiting | Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in HIV-Infected Children | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: TPV/r; Drug: TPV/r | |||||
| 26 | Terminated | A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients. | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: TPV500mg/RTV200mgBID; Drug: TPV500mg/RTV100mgBID; Drug: LPV400mg/RTV100mgBID | |||||
| 27 | Recruiting | Maraviroc as an Immunomodulatory Drug for Antiretroviral-Treated HIV Infected Patients Exhibiting Immunologic Failure | ||||
| Condition: | HIV Infection | |||||
| Interventions: | Drug: Maraviroc; Drug: Placebo | |||||
| 28 | Not yet recruiting | Safety and Effectiveness of Addition of Maraviroc to ART Regimens in HIV-Infected Adults With Suboptimal CD4 T-Cell Count Recovery Despite Sustained Virologic Suppression | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Maraviroc | |||||
| 29 | Recruiting | Clinical Trial of CNS-Targeted HAART (CIT2) | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: FDA Approved Antiretroviral Therapy (see list below) | |||||
|
